GlassScriptPhysician profile
Robert Dean Rosen
NPI 1760477335
$33,382.79
in general payments reported to CMS, 2019-2025
76 companies · $9,130 in 2025
The $9,130 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,471 · 2020: $2,403 · 2021: $3,814 · 2022: $3,262 · 2023: $3,544 · 2024: $4,760 · 2025: $9,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,494 · Consulting Fee: $5,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,463 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $650 · Travel and Lodging: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,493.88 |
| Consulting Fee | $5,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,462.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $650.00 |
| Travel and Lodging | $626.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,101.85 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $3,330.90 | 2019-2025 | Farxiga, Airsupra, Flumist Quadrivalent |
| Novo Nordisk INC | $3,167.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $3,055.10 | 2019-2023 | |
| Pfizer INC. | $1,819.02 | 2019-2025 | |
| Abbvie INC. | $1,650.22 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $1,451.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,092.54 | 2019-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $844.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $809.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $644.98 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $517.06 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $391.46 | 2019-2023 | Veozah, Myrbetriq |
| Allergan, INC. | $368.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $365.38 | 2021-2025 |
Show all 68 companies
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.